Nicotinamide for skin-cancer chemoprevention in transplant recipients (ONTRANS): a randomized trial
Allen NC, Martin AJ, Snaidr VA
Published in New England Journal of Medicine
Key Findings
Nicotinamide did not reduce new keratinocyte carcinomas in organ transplant recipients over 12 months.
Conclusions
Well-powered null result in immunosuppressed patients.
Limitations
Population differs from immunocompetent trials.
Supplements Studied
Nicotinamide did not reduce new keratinocyte carcinomas in organ transplant recipients over 12 months.
Oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients.
Outcomes Measured
Oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.